alpha-Interferon in the treatment of chronic viral hepatitis: effects on fibrogenesis serum markers
- PMID: 8340603
- DOI: 10.1016/s0168-8278(05)80018-2
alpha-Interferon in the treatment of chronic viral hepatitis: effects on fibrogenesis serum markers
Abstract
Forty patients with chronic viral hepatitis or active cirrhosis (33 anti-HCV positive) entered a recombinant human alpha 2A interferon randomized trial. Twenty-one subjects were treated with 6 million units (MU) three times per week for 6 months. Nineteen were not treated. Six months later in 12 patients of the treated group (60% of the evaluable 20) with normalized serum aminotransferases levels (responders), fibrogenesis serum markers (NPIIIP and laminin) were significantly lower than baseline. In the untreated patients and in non-responders NPIIIP and laminin were unchanged. Semi quantitative histological evaluation (allotting scores for inflammation, necrosis and fibrosis) confirmed a significant improvement of necro-inflammation in the responders. These data suggest that alpha-IFN treatment may decrease stimuli for fibrogenesis by reducing liver inflammation and necrosis, thus preventing evolution to cirrhosis.
Comment in
-
New challenges in hepatic fibrosis.J Hepatol. 1993 Apr;18(1):1-4. doi: 10.1016/s0168-8278(05)80002-9. J Hepatol. 1993. PMID: 8340600 Review.
Similar articles
-
Long-term variations of serum laminin and procollagen III peptide in chronic HCV hepatitis after alpha-interferon therapy.Ital J Gastroenterol. 1996 Jan;28(1):15-9. Ital J Gastroenterol. 1996. PMID: 8743068
-
Serum markers of hepatic fibrogenesis in chronic hepatitis type C treated with alfa-2A interferon.Liver. 1994 Oct;14(5):257-64. doi: 10.1111/j.1600-0676.1994.tb00085.x. Liver. 1994. PMID: 7997085 Clinical Trial.
-
[Serum variations of 2 markers of fibrogenesis in chronic hepatitis C treated with alpha interferon].Recenti Prog Med. 1997 Feb;88(2):73-6. Recenti Prog Med. 1997. PMID: 9148370 Italian.
-
[Treatment with interferon alfa-2b in patients with chronic hepatitis caused by hepatitis C virus: predictive factors for the response, relapse and early development to cirrhosis after treatment].Rev Esp Enferm Dig. 1996 Sep;88(9):609-15. Rev Esp Enferm Dig. 1996. PMID: 8962775 Review. Spanish.
-
Exacerbation of primary biliary cirrhosis during interferon-alpha 2b therapy for chronic active hepatitis C.Dig Dis Sci. 1995 Jun;40(6):1226-30. doi: 10.1007/BF02065528. Dig Dis Sci. 1995. PMID: 7781437 Review.
Cited by
-
Risks and benefits of interferon-alpha in the treatment of hepatitis.Drug Saf. 1995 Nov;13(5):304-16. doi: 10.2165/00002018-199513050-00004. Drug Saf. 1995. PMID: 8785018 Review.
-
Alpha-interferon improves liver fibrosis in chronic hepatitis C: clinical significance of the serum N-terminal propeptide of procollagen type III.Dig Dis Sci. 2001 Aug;46(8):1684-9. doi: 10.1023/a:1010649403659. Dig Dis Sci. 2001. PMID: 11508668
-
Interferon for interferon naive patients with chronic hepatitis C.Cochrane Database Syst Rev. 2002;2002(2):CD000370. doi: 10.1002/14651858.CD000370. Cochrane Database Syst Rev. 2002. PMID: 12076394 Free PMC article.
-
Effects of a 24-week course of interferon-alpha therapy after curative treatment of hepatitis C virus-associated hepatocellular carcinoma.World J Gastroenterol. 2007 Oct 28;13(40):5343-50. doi: 10.3748/wjg.v13.i40.5343. World J Gastroenterol. 2007. PMID: 17879404 Free PMC article.
-
Histological outcome of chronic hepatitis B in children treated with interferon alpha.World J Gastroenterol. 2005 Dec 7;11(45):7179-82. doi: 10.3748/wjg.v11.i45.7179. World J Gastroenterol. 2005. PMID: 16437668 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials